Axogen, Inc. Announces Merger Agreement to Acquire BioCircuit

What Happened
Axogen, Inc. (AXGN) filed a Form 8-K disclosing that it entered into an Agreement and Plan of Merger dated September 9, 2026, among Axogen, its subsidiary Omega Merger Sub, Inc., BioCircuit Technologies, Inc., and Michelle Jarrard as representative of BioCircuit’s equityholders. The company also furnished a corrected investor presentation as Exhibit 99.2 to the amendment filed September 10, 2026. The Original Form 8-K remains unchanged except for the corrected presentation.

Key Details

• Agreement and Plan of Merger dated: September 9, 2026 (filed as Exhibit 2.1).
• Corrected investor presentation furnished as Exhibit 99.2 on September 10, 2026.
• Omitted schedules/exhibits noted under Item 601(a)(5) and 601(b)(2); Axogen will provide them to the SEC on request.
• Form 8-K amendment signed by Marc Began (EVP, General Counsel & Chief Compliance Officer) on September 10, 2026.

Why It Matters
This filing reports a material, definitive transaction: Axogen has agreed to merge with/acquire BioCircuit Technologies, which could affect Axogen’s business, product lineup and future financial results. Investors should watch for forthcoming SEC filings and disclosures (including purchase price, financing, closing conditions and expected timing) for details that will determine the transaction’s financial impact. The corrected investor presentation may contain updated investor-facing details about the deal.